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1. Introduction 
Recently, researchers have shown an increased interest in the investigations of drug stability 
and degradation pathway. Baertschi (2006) and Alsante et al., (2007) described an overall 
strategy for the prediction, identification and control of stability-related issues in active 
pharmaceutical ingredients (APIs) and drug products using stress testing. Forced 
degradation studies are part of the drug development strategy being undertaken to 
elucidate the intrinsic stability of the drug. Such studies are conducted under more severe 
and exaggerated conditions than those usually used for long-term stability tests. These 
studies are particularly useful to establish the drug degradation pathway and validate the 
suitable analytical procedures (Jocić et al., 2009). 
Technetium-99m ethyl cysteinate dimer (Tc-99m-ECD or bicisate) is one of the most 
essential single-photon emission computed tomography (SPECT) imaging agents. In 
according to the practice guidelines of the American College of Radiology (ACR) (Abdel-
Dayem, 2003) and the European Association of Nuclear Medicine Neuroimaging Committee 
(ENC) (Kapucu et al., 2009), clinical indications of Tc-99m-ECD include in evaluating the 
regional cerebral blood flow (rCBF) in patients with cerebrovascular diseases, transient 
ischemic attack, various forms of dementia, symptomatic traumatic brain injury, 
encephalitis, vascular spasm following subarachnoid hemorrhage, inflammation, epileptic 
foci and lacunar infarctions. 
More indications of Tc-99m-ECD in SPECT brain perfusion imaging of neuropsychiatric 
disorders and chronic fatigue syndrome have not been fully characterized (Abdel-Dayem, 
2003; Kapucu et al., 2009). However, investigations of the conversion in patients of mild 
cognitive impairment to Alzheimer’s disease (AD) (Borroni et al., 2006), the functional 
compensation mechanism in incipient AD (Caroli et al., 2010), the mechanism for 
suppression of parkinsonian tremor by thalamic stimulation (Wielepp et al., 2001), the 
mechanism by which thyroid hormone availability affects cerebral activity (Schraml et al., 
2006), brain glucose metabolism in hypothyroidism (Bauer et al., 2009), reduction in the 
bifrontal regions and diffusion-weighted imaging of Creutzfeldt-Jacob disease (Sunada et 
al., 2004; Ukisu et al., 2006), quantitation and differentiation in patients with Tourette’s 
syndrome (Diler et al., 2002; Chen et al., 2003; Sun et al., 2001) and abnormal rCBF in 
patients with Sjögren’s syndrome (Chang et al., 2002) were reported. 
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Fig. 1. Chemical structures of ECD and its DPs 
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For clinical implements, Tc-99m-ECD is obtained by radiolabeling of Tc-99m to its API, i.e. 
L-Cysteine, N,N’-1,2-ethanediylbis-, diethyl ester, dihydrochloride (ECD) (Fig. 1). Despite its 
safety and efficacy, a major drawback for the application of Tc-99m-ECD is the stability of 
ECD Kit in aqueous solution. For example, no more delay for patient injection that longer 
than 30 minutes is recommended by ACR and EANM (Abdel-Dayem, 2003; Kapucu et al., 
2009). 
So far, several studies investigating stability and degradation of ECD and Tc-99m-ECD have 
been reported, but there is still insufficient data for the elucidation of degradation products 
(DPs) structure and pathway. Mikiciuk-Olasik et al. (2000) demonstrated that ECD 
decomposed as soon as it was dissolved in phosphate buffer solutions. However, they 
offered no explanation for the structures of three decomposition products. Verduyckt et al. 
(2003) investigated the identity of Tc-99m-ECD using radio-LC-MS and reported five DPs 
for ECD including disulfide, monoacid monoester (ECM), diacid (EC) and Sn(IV) complexes 
with ECD (Sn-ECD) and EC (Sn-EC) derivatives. However, no systematic degradation study 
was reported to investigate the degradation mechanism or pathway on ECD Kit. The study 
of Tsopelas et al. (2005) was mainly focused on the behavior of Tc-99m and its reactions with 
components of ECD Kit. 
 
Fig. 2. Overall scheme for the ECD and ECD Kit degradation studies 
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Our preliminary observations showing that ECD Kit is highly unstable in (non)aqueous 
solution and the composition of ECD Kit is the major obstacle to determine stability of ECD 
(Chao et al., 2011). Therefore, the aim of this paper is to evaluate degradation kinetics and 
mechanism of ECD Kit in aqueous solution. No previous reports were found in the 
literature regarding the degradation behavior of ECD. The main issues addressed in this 
study were modified according to the procedures outlined by Shah et al. (Shah & Singh, 
2010; Shah, et al., 2010; Raijada et al., 2010). The overall scheme in this degradation 
investigation (Fig. 2) includes: (i) development and validation of an HPLC method for 
determination of ECD and DPs, (ii) implement of the degradation and stress studies on ECD 
and ECD Kit, (iii) analysis of the DPs by HPLC, (iv) characterization of the molecular 
weights and collision activated dissociation (CAD) fragmentation pathways of ECD and 
DPs by Q1, MS/MS and TOF, (v) elucidation of the DPs’ structures and (vi) establishment of 
the ECD degradation pathways and decomposition mechanisms. 
 
2. Experimental 
2.1 Materials and reagents 
ECD (purity: 97.53%) was obtained from ABX (Radeberg, Germany). All chemicals and 
reagents were of analytical grade and used as received without further purification. 
Methanol (MeOH) (HPLC grade) was obtained from Merck (Darmstadt, Germany). 
Deionized water was purified using a Smart DQ3 reverse osmosis reagent water system 
(Millipore, MA, U.S.A.) with a 0.22-μm filter, TOC < 5 ppb, resistivity ≥ 18.2 MΩ-cm and 
endotoxin < 0.001 EU/mL. 
 
2.2 HPLC instrumentation 
An Agilent 1100 series high performance liquid chromatography (HPLC) (Agilent, Palo 
Alto, CA, U.S.A.) was employed, consisting of an on-line degasser, binary pump, 
autosampler, thermostated column oven and photodiodearray detector (PDA). Data were 
acquired and processed with ChemStation (Agilent, Palo Alto, CA, U.S.A.). A C-18 reversed-
phase column (Zorbox Eclipse XDB-C18, 4.6 × 50 mm, 1.8 μm, Agilent) was used for the 
separation of ECD and DPs. An isocratic elution was achieved using a mobile phase which 
consisted of methanol and sodium acetate (pH 7.0, 50 mM; 60 : 40, v/v). The flow-rate was 
0.5 mL/min and the injection volume was 2-5 μL. The absorbance detection wavelength was 
210 nm. The column temperature was set at 25°C in all experiments performed. 
 
2.3 LC-MS/MS and MS/TOF instrumentation 
MS analysis was carried out on a 4000 QTrap LC-MS/MS system with API Analyst software 
of version 1.4.1 or a QSTAR Elite Hybrid QTOF with API Analyst QS software of version 2.0 
(MDS Sciex, Ontario, Canada). Samples were introduced by an HPLC system (Agilent 1100 
series HPLC system, Agilent, CA, U.S.A.) or a syringe pump (Harvard, Harvard Apparatus 
Inc., Holliston, MA, U.S.A.). The samples were ionized by a turbo spray ion source 
(electrospray ionization) in the positive ion mode at 5500 V. Mass spectra were obtained 
over the range of 50 or 100 to 2000 amu with unit resolution in Q1 and Q3. Other parameters 
are shown in Table 1. In all cases of 4000 QTrap LC-MS/MS studies, nitrogen was used as 
the nebulization, curtain and collision gas. 
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2.4 HPLC method development and validation 
The method was validated according to the International Conference on Harmonization 
(ICH) guidelines for the validation of analytical methods, which includes specificity, 
linearity, precision, accuracy, LOD/LOQ, solution stability, robustness and system suitability 
and was achieved as the procedures described earlier (Liu et al., 2008; Yang et al., 2010). 
2.4.1 Specificity (selectivity) 
Forced degradation studies are used to evaluate the development of analytical methodology 
(the specificity or selectivity of the purity assay method), to gain better understanding of the 
stability of APIs and drug products and to provide information about degradation 
pathways and DPs. 
 
Parameter Q1 scan MS2 scan TOF MS 
Source Type Turbo Spray Turbo Spray Turbo Spray 
Source Temperature (°C) - - - 
Scan Type Q1 MS Product Ion (MS2) Positive TOF 
Scan Mode Profile Profile None 
Polarity Positive Positive Positive 
Resolution (Q1 & Q3) Unit Unit Unit 
Nebulizer Gas (NEB) - - - 
Curtain Gas (CUR) 10 10 20 
IonSpray Voltage (IS, V) 5500 5500 5500 
Collision Gas (CAD) - Medium - 
Ion Source Gas 1 (GS1) 20 20 20 
Ion Source Gas 2 (GS2) 0 0 0 
Ion Energy 1 (IE1, V) 0.30 0.30 1.00 
Ion Energy 3 (IE3, V) - -0.50 - 
Detector Parameters Positive Positive - 
Deflector (DF) - - - 
Channel Electron Multiplier (CEM, V) 1950 1950 - 
Table 1. Mass spectrometry working parameters for ECD and DPs analysis 
Here, forced degradation studies of ECD were carried out under the conditions of acidic and 
alkaline hydrolysis, oxidation and dry heat. Samples of ECD (2 mg) were dissolved in 0.34 
mL of methanol and subjected to 0.33 mL of 1 M HCl and 0.33 mL of 1 M NaOH at ambient 
temperature for 4 hrs and 1 hr, respectively. Acidic and alkaline hydrolysis samples were 
neutralized using 1 M NaOH or 1 M HCl and diluted to 2 mg/mL with methanol before 
HPLC analysis. Equivalent amounts (2 mg) of ECD that one portion was dissolved in 0.50 
mL of methanol and subjected to 0.50 mL of 3% H2O2 and the other portion of solid drug 
was heated at 50°C (in oven over a period of 4 hrs) and were injected into the HPLC for 
analysis. 
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2.4.2 Linearity 
The calibration curves of five concentrations (1.6 to 2.4 mg/mL) were obtained by plotting 
the respective peak areas against concentrations. The linearity was evaluated by the linear 
least square regression method with three determinations at each concentration. 
2.4.3 Precision 
In relation to the precision of the method, repeatability (intra-day), intermediate (inter-day) 
precision and reproducibility were investigated by performing assays of retention times, 
peak widths at half height, number of theoretical plates, linear least squares regression 
equations and correlation coefficients for the ECD standard at five concentrations and 
purities for one quality control (QC) sample. The repeatability and intermediate precision 
were evaluated by one analyst within one and two days, respectively, while the 
reproducibility was achieved by two analysts (Kulikov & Zinchenko, 2007). 
2.4.4 Accuracy (recovery) 
The accuracy of the method was determined by the recovery test. QC samples of ECD of 
concentration at 2.0 mg/mL (Cnominal) were analyzed by the proposed method. Experimental 
values (Cexp) were obtained by interpolation to the linear least square regression equation of 
a fresh newly prepared calibration curve (1.6 to 2.4 mg/mL) and comparing with the 
theoretical values (Cnominal). 
Recovery yield (%) = 
  Cexp (mg/mL)  
  Cnominal (mg/mL)  
 × 100% 
2.4.5 Limit of detection (LOD) and limit of quantification (LOQ) 
The LOD and LOQ of the method for impurities in ECD were determined at signal to noise 
ratios of 3 and 10, respectively. 
2.4.6 Stability of drug (API) solution 
The stability of the API solution was examined using the QC sample (2.0 mg/mL) for bench-
top stability study. The QC samples were kept in the autosampler at ambient temperature 
for HPLC analysis over three consecutive days. Experimental data were obtained by 
interpolation to the linear least square regression equation of a calibration curve (1.6 to 2.4 
mg/mL) newly prepared each day. Retention time, recovery yield and purity of ECD over 
three consecutive days were analyzed. 
2.4.7 Robustness 
The robustness of an analytical method is a basic measurement of its capacity to remain 
unaffected by small variations in method parameters. In this investigation, method 
robustness was evaluated through the effects of different columns (same type and 
manufacturer), column temperatures (± 2°C), pH values (± 0.1) and flow rates (± 0.05 
mL/min) of mobile phase. 
2.4.8 System suitability 
The system suitability was assessed by five triplicate analyses of the drug in a concentration 
range of 1.6 to 2.4 mg/mL. The efficiency of the column was expressed in terms of the 
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theoretical plates number (N), column capacity (k’), column selectivity (α) and tailing factor 
(t). The acceptance criteria for the N, k’, α, t and percentage relative standard deviation  
(% R.S.D.) for the retention time of ECD were > 3000, 2-8, 1.05-2.00, 0.9-2.5 and ± 2%, 
respectively. 
2.5 Forced degradation studies of ECD 
Forced degradation studies of ECD were carried out according to the procedures described 
above in Section 2.4.1 Specificity (selectivity). Moreover, samples of ECD (2 mg) were 
dissolved in 0.50 mL of methanol and subjected to 0.25 mL of 1 M NaOH and 0.50 mL of 3% 
H2O2 at ambient temperature for kinetic studies. The structures and degradation of DPs 
were further characterized by HPLC and LC-MS/MS for the molecular weights and the 
CAD fragmentation pathways. 
2.6 Degradation studies of ECD Kit 
First, degradation studies of ECD Kit were carried out by subjecting samples of ECD to 
various components of ECD Kit for determining the effect of SnCl2, mannitol and EDTA. 
Second, ECD (1 mg/mL, 500 μL) and SnCl2 (1 mg/mL) were mixed in ratio of 12.5 : 1, 8 : 1,  
4 : 1, 2 : 1 and 1 : 1 (v/v) and diluted to total volume of 1000 μL with deionized water. The 
mixtures were kept at ambient temperature in HPLC autosampler and in bench-top for 
HPLC and MS analysis, respectively. All samples were diluted to 1 ppm with methanol for 
MS analysis. Positive ESI-MS/MS scanning types, i.e. precursor ion scan, product ion scan 
and neutral loss scan were performed. The structures of DPs were proposed based on the 
molecular weights and the CAD fragmentation pathways. 
3. Results and discussion 
3.1 HPLC method development 
A reversed-phase high performance liquid chromatography (RP-HPLC) method for the 
determination of ECD and forced degradation DPs was developed and validated. A Zorbox 
Eclipse XDB-C18 (4.6 × 50 mm, 1.8 μm, Agilent) reversed-phase column was selected for the 
separation of ECD and DPs. ECD samples at concentrations of around 2 mg/mL and 100 
ppb were used to optimize conditions for HPLC and LC-ESI-MS/MS, respectively. 
Absorption spectra of ECD were recorded over the range of 200 to 300 nm by a post-column 
photodiode-array detector (PDA). A wavelength of 210 nm was found to be optimal for the 
detection and quantification of ECD. 
Chromatographic separation of ECD was achieved using a mobile phase which consisted  
of methanol and sodium acetate (pH 7.0, 50 mM; 60 : 40, v/v). The typical HPLC 
chromatograms of ECD are shown in Fig. 3(a) and 4(a). The difference of retention time (tR) 
of ECD chromatograms between degradation studies of API and drug product was due to 
the gradual damage of column packing materials. However, no significant efficiency of the 
column, such as the number of theoretical plates (N) and tailing factor (t) was found. 
3.2 Mass spectrometric analysis of ECD 
The proposed high-salt contained mobile phase of HPLC was not suitable for ESI-MS 
studies. Therefore, a syringe pump was chosen for the sample introduction for Q1 and 
MS/MS scan. Q1 full scans were achieved in a positive ion mode to optimize the 
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Fig. 3. Typical HPLC chromatograms of degradation studies of ECD. Samples (2 mg of ECD) 
were carried out under the conditions of (a) methanol (no degradation), (b) acidic hydrolysis 
(0.5 M HCl at ambient temperature for 4 hrs), (c) alkaline hydrolysis (0.5 M NaOH at 
ambient temperature for 1 hr), (d) oxidation (1.5% H2O2) and (e) dry heat (50°C for 4 hrs) 
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electrospray ionization (ESI) conditions of ECD and (ECD)2 (Fig. 5(a)). The peaks at 
retention time (tR) of 4.43 and 3.82 min were identified as a protonated ECD ion ([M+H]+) at 
m/z 323.4 by ESI-MS (Fig. 5(b)). Moreover, a protonated molecular ion with m/z 645.4 at tR 
of 6.17 and 5.27 min were identified as ECD dimer (DP#3), i.e. (ECD)2 (Fig. 5(g)).  
Both product ion and precursor ion scans were then carried out at different collision-
activated dissociation (CAD) conditions to optimize the declustering potential (DP), 
entrance potential (EP), collision energy (CE) and collision cell exit potential (CXP). The 
MS/MS fragments of ECD, ECD and ECDS-S are summarized in Table 2. 
The linearities of multiple reaction monitoring (MRM) transitions of ECD (ECDS-S) were 
studied. The linear least-square regression equations and correlation coefficients of MRM 
transitions showed a good linearity over the calibration range. The correlation coefficients 
(r) were all above 0.9980, indicating the stability of these fragmentations (data not shown). 
Tandem mass spectrometry (MS/MS) experiments performed in a QTrap MS were used to 
investigate the CAD fragmentation behavior of ECD (ECDS-S) (Fig. 6(a)). 
Although precursor scan of m/z 323.50 can show its precursor ion at m/z 325.40 and 646.36, 
we found that intra-molecular disulfide product (ECDS-S) is the prominent form in aqueous 
solution than ECD. This is consistent with previous experiment by Verduyckt et al. (2003), in 
which they pointed out the existence of disulfide and incomplete esterification of ethylene 
dicysteine derivatives. 
 
 
Fig. 4. Typical HPLC chromatograms of degradation studies of ECD Kit. Samples were 
carried out by subjecting ECD to SnCl2 in ratio (v/v) of (a) 1 : 0, (b) 12.5 : 1, (c) 8 : 1, (d) 4 : 1 
and (e) 2 : 1. Duration time is 7-8 hrs 
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(a) 
 
 
(b) 
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(c) 
 
 
(d) 
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(e) 
 
 
(f) 
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(g) 
 
 
(h) 
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(i) 
 
 
(j) 
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(k) 
 
 
(l) 
Fig. 5. (a) Typical ESI-MS Q1 spectra of ECD, typical ESI-MS/MS product ion spectra of (b) 
ECDS-S (m/z 323.4), (c) DP#1 (ECD-Et, m/z 297.5), (d) DP#1’ ((ECD)S2N2-Et, m/z 295.4), (e) 
DP#2 (ECD-2Et, m/z 268.5), (f) DP#2’ ((ECD)S2N2-2Et, m/z 266.5), (g) DP#3 ((ECD)2, m/z 
645.4), (h) DP#4 (Sn(ECD)2, m/z 766.4), (i) DP#5 (Sn(ECD)2-Et, m/z 738.0), (j) isotopic ESI-
TOF spectra of DP#4 (Sn(ECD)2) and DP#5 (Sn(ECD)2-Et), (k) DP#6’ (Sn(ECD)S2N2, m/z 
442.0) and (l) DP#7’ (Sn(ECD)S2N2-Et, m/z 414.0) 
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ECD and DPs Molecular Formula
mwavg or 
mwmax† 
Major fragments 
(m/z) 
 ECD C12H24N2O4S2 324.46 
175.72, 147.79, 132.53, 129.30, 
119.47, 101.52, 86.53 
 ECDS-S C12H22N2O4S2 322.45 
323.33, 249.18, 215.27, 208.20, 
191.42, 174.15, 146.11, 130.24, 
117.11, 102.28, 88.18, 73.96 
DP#1 ECD-Et C10H20N2O4S2 296.41 
297.46, 180.34, 148.35, 102.44, 
74.30 
DP#1’ ECDS-S-Et C10H18N2O4S2 294.39 
295.40, 313.30, 248.40, 219.20, 
139.50, 117.40 
DP#2 ECD-2Et C8H16N2O4S2 268.36 
268.53, 289.50, 354.30, (322.40, 
304.53), 247.40, 215.52, 190.20, 
169.20, 110.45 
DP#2’ ECDS-S-2Et C8H14N2O4S2 266.34 266.52, 114.30 
DP#3 (ECD)2 C24H44N4O8S4 644.90 
389.74, 355.51, 321.57, 275.59, 
215.3, 208.45, 191.47, 174.41, 
130.33, 116.24, 102.46 
DP#4 Sn(ECD)2 C24H44N4O8S4Sn 764.80† 
441.61, 396.01, 367.20, 321.40, 
280.40 
DP#5 Sn(ECD)2-Et C22H40N4O8S4Sn 736.74† 
442.40, 413.69, 378.20, 346.70, 
324.84 
DP#6’ Sn(ECD)S2N2 C12H20N2O4S2Sn 440.33† 
395.83, 367.77, 349.47, 321.84, 
280.35, 268.20, 222.37 
DP#7’ Sn(ECD)S2N2-Et C10H16N2O4S2Sn 412.28† 
385.30, 367.77, 339.79, 321.51, 
311.55, 293.20, 279.52, 278.10, 
252.03, 222.42, 205.38, 124.96 
Table 2. Major MS/MS fragments of ECD and DPs. †mwmax: Theoretic molecular weight of 
maximum isotopic composition 
3.3 HPLC method validation 
3.3.1 Specificity (selectivity) 
ECD was firstly subjected to forced degradation under the conditions of hydrolysis (acid, 
alkali and neutral), oxidation and thermal stress as requirements of ICH. Significant 
degradations of 0.5 M NaOH and 1.5% hydrogen peroxide were noticed under stress 
conditions. Several DPs in the chromatograms at the tR of 6.64, 2.99, 2.17 and 1.00-1.50 min 
were detected as shown in Fig. 3(c) and 3(d). Fig. 3(b) and 3(e) represent the chromatograms 
of a sample degraded at 0.5 M HCl and 50oC for 4 hrs, respectively. No significant 
degradation was found in these cases. The resolutions between ECD and its degradation 
peaks were greater than 4.4, indicating that the proposed method was sufficiently selective 
for its intended purpose. 
3.3.2 Linearity 
Standard curves were constructed by plotting peak area against concentration of ECD and 
were linear over the concentration range of 1.6 to 2.4 mg/mL. The linear least squares 
regression equation of the standard curve correlating the peak areas (PAs) to the drug 
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concentration (X in mg/mL) in this range was Y = 832.03X - 148.88. The correlation 
coefficient (r) was 0.9991. 
3.3.3 Precision 
The results of repeatability, intermediate precision and reproducibility were demonstrated 
by analysing ECD at five concentrations and one QC sample (Table 3). Although the number 
of theoretical plates were decreased for ~20%, no significant difference in the retention times, 
peak widths at half height, linear least squares regression equations and correlation 
coefficients were found. The difference of purities (P (%)) could be due to the stability 
(equilibrium) and uniformity of QC samples, but also might indicate the sufficient resolution 
of the proposed method. 
 
Parameters tR (min) 
Whalf 
(min)† 
N† L eq.† r P (%)‡ 
Analyst 1, 
Day 1 
4.42 ± 0.00 
(0.05%) 
0.15 ± 0.00 
(1.27%) 
5007 ± 129 
(2.58%) 
Y = 859.35X - 
204.71 
0.9998 100.30 ± 0.01 
Analyst 1, 
Day 2 
4.42 ± 0.00 
(0.06%) 
0.15 ± 0.00 
(0.69%) 
4933 ± 66 
(1.34%) 
Y = 910.18X - 
244.25 
0.9992 99.20 ± 0.02 
Analyst 2, 
Day 3 
4.41 ± 0.00 
(0.05%) 
0.16 ± 0.00 
(0.81%) 
4174 ± 67 
(1.61%) 
Y = 834.46X - 
127.08 
0.9990 97.42 ± 0.00 
Table 3. Repeatability, intermediate precision and reproducibility of ECD analysis. †Linear 
range: 1.6 to 2.4 mg/mL; Whalf: Peak width at half height; N: Number of theoretical plates;  
n = 15. ‡P (%): The purity of QC sample (n = 3) 
3.3.4 Accuracy (recovery) 
Recovery tests were achieved by comparing the concentration (Cexp) obtained from injection 
of QC samples to the nominal values (Cnominal). The intra-day recovery of ECD at 
concentration of 1.95 mg/mL was 99.68 ± 0.48%. The recoveries, 99.14, 99.89 and 100.03% 
were between 97 and 103%, indicating that there was sufficient accuracy in the proposed 
method. The % R.S.D. for measurement of accuracy was 0.48%. 
3.3.5 Limit of detection (LOD) and limit of quantification (LOQ) 
The limits of detection (LOD, S/N = 3/1) and quantification (LOQ, S/N = 10/1) for the 
major impurity (DP#3, average abundance in percentage of peak area = 1.32 ± 0.07%) in 
ECD were found to be 0.004 and 0.014 mg/mL (n = 3), respectively. 
3.3.6 Stability of drug (API) solution 
The stability of ECD solutions was examined by analyzing solutions over 3 days. The results 
of these studies are shown in Table 4, where the tR of ECD and the recovery and purity of 
QC samples were within the range of 97-103%. No significant degradation or reduction in 
the absolute peak area was observed within three days, indicating that ECD standard 
solution would be stable for at least three days when kept on a bench top. 
3.3.7 Robustness 
The robustness of an analytical procedure is a measurement of its capacity to remain 
unaffected by small, but deliberate, variations in method parameters and provides an 
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indication of its reliability during normal usage. In this case, robustness of the method was 
investigated by making small changes of column parameters, column temperature, mobile 
phase pH and flow rate. The results of the robustness studies were within acceptable range, 
except that one theoretical plates number (N) was less than 3000, as indicated in Table 5. 
However, no critical change in performance was found. 
 
Day Calibration 
range (mg/mL)
L eq. r tR (min)† P (%)† 
1 1.51-2.33 Y = 859.35X - 204.71 0.9998 4.42 ± 0.00 (0.05%) 100.30 ± 0.97 (0.97%) 
2 1.58-2.44 Y = 910.18X - 244.25 0.9992 4.42 ± 0.00 (0.06%) 99.66 ± 1.07 (1.08%) 
3 1.54-2.36 Y = 834.02X - 114.17 0.9948 4.40 ± 0.00 (0.04%) 100.13 ± 1.14 (1.14%) 
Table 4. Bench-top stability studies of ECD. †The retention time and purity results of QC 
samples (n = 3) 
 
Parameters tR (min) Whalf (min) N L eq. R P (%)* 
Column† #1 
4.49 ± 0.00 
(0.05%) 
0.19 ± 0.00 
(1.46%) 
n. r.# 
Y = 842.24X - 
138.39 
0.9984 98.99 ± 0.12 
 #2 
4.42 ± 0.00 
(0.05%) 
0.15 ± 0.00 
(1.27%) 
5007 ± 129 
(2.58%) 
Y = 859.35X - 
204.71 
0.9998 
100.30 ± 
0.97 
Temperature (oC) 25 
4.41 ± 0.00 
(0.05%) 
0.16 ± 0.00 
(0.81%) 
4174 ± 67 
(1.61%) 
Y = 834.46X - 
127.08 
0.9990 97.42 ± 0.28 
 27 
4.35 ± 0.00 
(0.07%) 
0.17 ± 0.00 
(1.83%) 
3698 ± 138 
(3.74%) 
Y = 849.90X - 
154.71 
0.9996 97.13 ± 0.22 
pH‡ 6.9 
4.41 ± 0.00 
(0.08%) 
0.14 ± 0.00 
(0.75%) 
5418 ± 84 
(1.55%) 
Y = 860.08X - 
227.29 
0.9983 99.21 ± 0.87 
 7.0 
4.42 ± 0.00 
(0.05%) 
0.15 ± 0.00 
(1.27%) 
5007 ± 129 
(2.58%) 
Y = 859.35X - 
204.71 
0.9998 
100.30 ± 
0.97 
 7.1 
4.40 ± 0.00 
(0.09%) 
0.15 ± 0.01 
(5.11%) 
4777 ± 465 
(9.73%) 
Y = 900.62X - 
270.33 
0.9968 99.90 ± 0.06 
Flow rate 
(mL/min) 
0.45
5.00 ± 0.00 
(0.06%) 
0.25 ± 0.00 
(0.92%) 
2249 ± 43 
(1.90%) 
Y = 986.87X - 
253.74 
0.9967 
100.69 ± 
0.43 
 0.50
4.49 ± 0.00 
(0.05%) 
0.19 ± 0.00 
(1.46%) 
n. r.# 
Y = 842.24X - 
138.39 
0.9984 98.99 ± 0.12 
 0.55
4.08 ± 0.00 
(0.10%) 
0.18 ± 0.00 
(1.77%) 
n. r.# 
Y = 808.35X - 
177.83 
0.9981 98.75 ± 0.18 
Table 5. Robustness study of ECD calibration standard and QC samples analysis. †Column 
#1 and #2 refer to columns of same type, same manufacturer, but different batch. ‡The pH 
value of the original aqueous component. *P (%): The purity of QC sample. #n. r.: No record 
3.3.8 System suitability 
The theoretical plates number (N), column capacity (k’), column selectivity (α) and tailing 
factor (t) were 5007 ± 129 (2.58%), 2.85 ± 0.01 (0.18%), 1.31 ± 0.00 (0.00%) and 1.19 ± 0.01 
(1.07%), respectively. The repeatabilities (% R.S.D.) of tR for triplicate analysis were within 
the acceptance criterion range (± 2%). These results were within acceptable range. 
3.4 Forced degradation studies of ECD 
ECD was subjected to forced degradation under the conditions of hydrolysis (acid, alkali 
and neutral), oxidation and thermal stress as requirements of ICH. No significant 
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degradation product under the stress conditions of neutral solvents, acidic hydrolysis and 
dry heat was found (Fig. 3(a), 3(b) and 3(e)). On the contrary, the drug was demonstrated 
to be liable to degradation under the alkaline hydrolysis and oxidation stress conditions. 
The reaction in 0.5 M NaOH and 1.5% H2O2 at ambient temperature was so fast that almost 
100% of ECD was degraded within 1 hr and even immediately, respectively (Fig. 3(c) and 
3(d)). 
Several high polarity degradants of alkaline hydrolysis of esters in ECD, i.e. DP#1, DP#1’, 
DP#2 and DP#2’ were formed. The MS/MS spectra are presented in Fig. 5(c)-5(f) and the 
major fragments are summarized in Table 2. DP#1 and DP#1’ were shown to be monoacid 
monoester degradants of ECD and ECDS-S, whereas DP#2 and DP#2’ were diacid 
degradants of ECD and ECDS-S. These results are consistent with previous study (Verduyckt 
et al., 2003). The proposed structures of DP#1, DP#1’, DP#2 and DP#2’ are shown in Fig. 1 
Under oxidation condition of 1.5% H2O2, our results also demonstrated that: (i) MS/MS 
fragments of DP#1, DP#1’, DP#2 and DP#2’ can be detected within duration time less than 
0.5 hr, (ii) peak at tR of 0.97 min was a mixture of DP#1, DP#1’, DP#2 and DP#2’ and (iii) 
MS/MS intensities of DP#2 and DP#2’ were significantly weaker than those of DP#1 and 
DP#1’. 
Fragmentation ions at m/z 354.50, 322.40 and 304.53 (Table 2) can be detected in the 
precursor scan of DP#2 (mwavg = 268.36) when the duration time was increased to 1.0 hr, 
indicating that further oxidation might result in dimer formation. 
No protonated molecular ions of DP#1, DP#1’, DP#2 and DP#2’ were detected when SnCl2 
was added to the ECD aqueous solution, suggesting that concentrations of DP#1, DP#1’, 
DP#2 and DP#2’ were negligible in ECD Kit. 
Comparing to the degradation rate under oxidation condition, alkaline hydrolysis was 
much more complicate, and several degradation intermediates were found before they were 
degraded to DP#1, DP#1’, DP#2 and DP#2’ (Fig. 3(c)). 
3.5 Degradation studies of ECD Kit 
ECD was very stable in deionized water, methanol and DMSO. The purity of ECD was kept 
in 95% for 45 hours, whereas ECD Kit was very unstable for quick deceasing to purity of 
74.80% within 11 minutes. 
ECD was subjected to various components of ECD Kit, such as SnCl2, mannitol and EDTA, 
to investigate its degradation behavior. Bi-component mixtures of ECD and mannitol, EDTA 
and SnCl2 in variant of ratio and duration time were analyzed by HPLC, MS and MS/MS. 
Our preliminary results showed that mannitol and EDTA had no significant degradation 
effect in ECD and thus did not affect the purity of ECD. In contract to mannitol and EDTA, a 
positive correlation between ECD degradation and stannous chloride (SnCl2) was found, 
suggesting that ECD degradation is significantly correlative to the ratio of ECD to SnCl2 and 
duration time. These results demonstrated that SnCl2 was the leading cause (key factor) for 
ECD degradation in ECD Kit. Therefore we prepared mixtures of ECD (1 mg/mL, 500 μL) 
and SnCl2 (1 mg/mL) in ratio of 12.5 : 1 (the ratio of ECD to SnCl2 in ECD Kit), 8 : 1, 4 : 1, 2 : 
1 and 1 : 1 (v/v) and diluted to total volume of 1000 μL with deionized water. The mixtures 
were kept at ambient temperature in HPLC autosampler and in bench-top for HPLC and MS 
analysis, respectively. 
Six major DPs of ECD, i.e. DP#3 - DP#7’ were numbered in sequence of the coordination 
number of ECD with Sn and hydrolysis of ester group in ECD. Their MS/MS spectra are 
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shown in Fig. 5(g)-5(l). These results did not quantify the effects on SnCl2 on ECD 
degradation in detail due to the fact that the liability of SnCl2 for oxidation in aqueous from 
Sn(II) to Sn(IV) make it difficult to exactly control the concentration of SnCl2. 
 
 
(a) 
 
 
(b) 
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(c) 
 
 
(d) 
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(e) 
 
 
(f) 
Fig. 6. Proposed CAD fragmentation pathways of the protonated molecules of (a) ECDS-S 
(m/z = 323.4), (b) Sn(ECD)S2N2 (m/z = 442.0), (c) (ECD)2 (m/z = 645.4), (d) Sn(ECD)2-Et 
(m/z = 738.0), (e) Sn(ECD)2 (m/z = 766.4) and (f) Sn(ECD)S2N2-Et (m/z = 414.0) 
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3.5.1 Degradation product, DP#3 
Here, we have identified the degradation production with intermolecular disulfide bond as 
(ECD2), i.e. DP#3. The structure of DP#3 is shown in Fig. 1. In the HPLC chromatograms, 
DP#3 was found in the neutral solvents, acidic hydrolysis, oxidation, thermal degradation 
(Fig. 3 and 4(a)) and solutions with low concentration of SnCl2 (Fig. 4(b) and (c)). 
The typical product ion (MS/MS) scan spectra of protonated molecular ion with m/z 645.4 
were identified as DP#3 (Fig. 5(g)). The MS/MS fragments of DP#3 are summarized in 
Table 2 and the linearities of MRM transitions were studied. The linear least-square 
regression equations and correlation coefficients (r > 0.9990) of MRM transitions showed a 
good linearity over the calibration range, indicating the stability of these fragmentations 
(data not shown). 
Proposed CAD fragmentation pathways of the protonated molecules of DP#3 at m/z = 
645.4 is presented in Fig. 6(c). 
No significant hydrolysis product of DP#3, i.e. (ECD)2-Et, (ECD)2-2Et, (ECD)2-3Et or (ECD)2-
4Et was detected in the MS scanning. Because species exchange reaction among ECD, ECDS-
S and (ECD)2 was found in the HPLC chromatograms, we suggested that DP#3, (ECD)2 can 
decompose reversibly into ECD or ECDS-S and degrade further. 
3.5.2 Degradation products, DP#4 and DP#5 
In the ECD to SnCl2 ratio of 12.5 : 1, 8 : 1 and 4 : 1 (v/v), one more nonpolar product (DP#4, 
tR = 6.04 min) when compared to ECD and its polar hydrolysis product (DP#5, tR = 1.68 min) 
were formed as indicated in Fig. 4(a)-(d). For higher concentration of SnCl2 (ratio = 2 : 1 and 
1 : 1), DP#4 was fast degraded and disappeared. The structures of DP#4 and DP#5 are 
shown in Fig. 1. The typical product ion (MS/MS) scan spectra of protonated molecular ions 
of DP#4 and DP#5 are shown in Fig. 5(h)-5(j). The MS/MS fragments of DP#4 and DP#5 are 
summarized in Table 2. Proposed CAD fragmentation pathways of the protonated molecules 
of DP#4 and DP#5 are shown in Fig. 6(e) and 6(d), respectively. 
The peaks that appeared in the protonated molecular ions with the m/z range of 732 to 770 
was further studied by TOF (Fig. 5(j)), the pattern was mainly due to the contribution of 
stable isotopes of tin and sulfur. Simulation spectra of DP#4 (Sn(ECD)2) and DP#5 
(Sn(ECD)2-Et) are shown in the inset of Fig. 5(j). The isotopic distribution pattern and 
isotopic abundances were similar and coincident with the simulation results calculated by 
the software of API ‘Isotopic Distribution Calculation’ (Analyst, version 1.4.1, MDS Sciex, 
Ontario, Canada). This finding is in agreement with our earlier report which showed that 
highest intensity peak was mainly contributed from the stable isotope Sn-120 (Yang et al., 
2010). However, in this case, isotopic composition of sulfur and tin were significantly 
complicated the MS spectra of Sn(ECD)2-Et and Sn(ECD)2 for determining of a 
fragmentation ion’s molecular weight and m/z. 
No significant DPs of Sn(ECD)2-2Et was found in the MS spectra. 
3.5.3 Degradation products, DP#6’ and DP#7’ 
In the ECD to SnCl2 ratio of 2 : 1 (v/v), only two high polarity products at tR of 0.93 and 1.14 
min were left (Fig. 4(e)). It indicated that they might be partial degradation products of 
DP#4 and DP#5 when compared to the spectra of lower SnCl2 solution (Fig. 4(d)). The 
typical product ion spectra and fragments of protonated molecular ions are shown in Fig. 
5(k)-5(l) and summarized in Table 2. Three possible structures of Sn(ECD) (DP#6, DP#6’ and 
DP#6’’) and Sn(ECD)-Et (DP#7, DP#7’ and DP#7’’) are proposed in Fig. 1, of which 
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Sn4+(ECD)S2N2 (DP#6’) and Sn4+(ECD)S2N2-Et (DP#7’) were considered to be the prominent 
ones. 
The experimental values of protonated molecular ions at m/zexp = 442.11 and 414.30 
supported this consideration. Moreover, there might be two possible explanations for this 
result. 
First, the proposed net reactions of Sn(II) to Sn(IV) in the existence of dissolved oxygen or 
H2O2 are spontaneous in the forward direction. The proposed net reactions are as follows: 
 1 
 2  O2 + 2H
+ + Sn2+ å H2O + Sn4+       Enet = 1.090 volt 
or 
H2O2 + 2H+ + Sn2+ å 2H2O + Sn4+       Enet = 1.625 volt 
Second, both sulfur and nitrogen have lone pair electron can donate to the electrophile, 
Sn(IV). Sulfur is more nucleophilic than nitrogen, therefore sulfur can bond to the 
electrophile and react with it faster than the nitrogen does. For an irreversible reaction, the 
molecules do not have a chance to find the most energetically stable formation, and so they 
stay in whatever shape they form first and nucleophiles determine what the products are (A 
Crystal Clear Chemistry Concepts Tutorial). Highest amounts of DP#6’was existed in the 
ratio of ECD to SnCl2 = 2 : 1 (v/v) and duration time of 4-7 hrs. Additionally, DP#7’ was 
existed only when the ratio of ECD to SnCl2 (w/w) was greater than 2:1 and duration time 
was longer than 2 hrs. These results indicated that DP#6’ and DP#7’ were reversible 
thermodynamic products. Proposed CAD fragmentation pathways of the protonated 
molecules of DP#6’ and DP#7’ are shown in Fig. 6(b) and 6(f), respectively. 
No significant DPs of Sn(ECD)S2N2-2Et was found. 
3.5.4 Degradation product, DP#8 
Surprisingly, m/z 872.1, 901.0 and 975.5 can be found in the precursor scan of m/z 441.0, 
indicating that ECD trimer might be existed. Although no significant Sn(ECD)(ECD)2 
(mwavg = 1086.05) can be detected in the MS spectra, it is reasonable to suggest a feasible 
structure and formation of DP#8 (trimer), i. e. Sn(ECD)(ECD)2 shown as in Fig. 7. It seems 
that these results are due to labile and further decomposition of Sn(ECD)(ECD)2. 
 
 
Fig. 7. Proposed formation mechanism of DP#8, Sn(ECD)(ECD)2 
3.6 Postulated degradation pathway of ECD and ECD Kit 
The degradation pathway of ECD (API) and ECD Kit is shown in Fig. 8. Under alkaline and 
oxidation conditions, the drug can form DP#1, DP#1’, DP#2 and DP#2’ through ester 
hydrolysis and intra-molecular disulfidation. Under oxidation conditions, inter-molecular  
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Fig. 8. Degradation pathway of ECD (API) and ECD Kit (drug product) 
disulfidation of ECD also resulted in the formation of DP#3, i.e. (ECD)2. For ECD Kit, the 
existence of SnCl2 inhibited the formation of DP#1, DP#1’, DP#2 and DP#2’. In the 
meantime, oxidation of Sn(II) to Sn(IV) promoted the Sn(IV)-ECD complexation with 
coordination number of 1 and 2 to DP#6’ and DP#4, respectively. DP#6’ and DP#4 was 
further hydrolyzed to monoacid monoester derivatives, i.e. DP#7’ and DP#5. Moreover, the 
detection of Sn-trimer demonstrated the existence of DP#8, i.e. Sn(ECD)(ECD)2. 
4. Conclusion 
The present study was designed to determine the factors affecting on the stability of ECD 
and ECD Kit and was given an account and the reasons for the use of Tc-99m-ECD which 
are suggested in practice guideline of ACR and EANM. The most interesting results 
emerging from the data are the degradation mechanisms and profiles of ECD. These 
findings enhance our understanding of ECD Kit about its stability, degradation pathways 
and structures of DPs. ECD is one of the diaminodithiol (DADT) derivatives to form stable 
complexes with radiorhenium or radiotechnetium. Therefore, the present study makes 
important implications for developing formulation of radiorhenium or radiotechnetium 
labeling pharmaceuticals. Further study for designing a more stable ECD Kit, such as a new 
reducing agent, reduction methodology or procedure is strongly recommended. 
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no errors have occurred.The quality which is supposed to be achieved is not a concept which can be
controlled by easy, numerical or other means, but it is the control over the intrinsic quality of a test facility and
its studies. The aim of this book is to share useful and practical knowledge about quality control in several
fields with the people who want to improve their knowledge.
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